包涵 李晓惠

    [摘要] 川崎病(KD)合并冠状动脉瘤导致血栓形成是KD的严重并发症，是患儿及其成年后严重的心脏疾病。KD的抗血栓治疗药物包括阿司匹林、氯吡格雷、华法林及双嘧达莫。这些药物在临床治疗中的个体化差异与遗传密切相关。目前，与阿司匹林相关基因研究尚无明确定论，而有关氯吡格雷研究较多且结论较为明确统一的基因为CYP2C19，与华法林相关的为CYP2C9和VKORC1，尚未发现双嘧达莫相关基因研究。这些研究结果大多来源于成人研究，且相关基因多态性已分为不同证据级别，为儿童抗血栓治疗研究提供了方向。

    [關键词] 川崎病；抗血栓治疗；阿司匹林；氯吡格雷；华法林；双嘧达莫；基因多态性

    [中图分类号] R725.4 [文献标识码] A [文章编号] 1673-7210(2019)04(b)-0034-04

    Advances in research on gene polymorphisms of antithrombotic drugs in Kawasaki disease

    BAO Han LI Xiaohui

    Department of Cardiovascular Medicine， Children′s Hospital， Capital Institute of Pediatrics， Beijing 100020， China

    [Abstract] Kawasaki disease (KD) with coronary artery aneurysm causing thrombosis is a serious complication of KD and a serious heart disease in children and their adulthood. Antithrombotic drugs include Aspirin， Clopidogrel， Warfarin and Dipyridamole. The individualized differences in the clinical treatment of these drugs are closely related to heredity. At present， there is no definite conclusion on Aspirin-related gene research， while more studies on Clopidogrel and more definite and unified conclusion are CYP2C19 and Warfarin-related are CYP2C9 and VKORC1 ......